While some people are still looking for a magic formula of eternal youth, others are actively using Metformin to delay aging. In fact, the so-called "anti-aging" medication is used to treat type 2 diabetes. However, the treatment has gained worldwide popularity of the anti-aging drug prototype. The medication has gained such a status since it cannot treat or warn aging, while it is powerful to significantly prolong youth. Metformin is an effective multi-functional preparation that is approved to treat type 2 diabetes. Nevertheless, it is not the only indication of the drug. When used off-label, the treatment can considerably affect ovulation problems in women, balance blood sugar levels, preserve cardiovascular system, etc. Long-term treatment with the type 2 diabetes drug metformin improves health and longevity of male mice when started at middle age, reports an international team of scientists led by researchers at the National Institute on Aging (NIA), part of the National Institutes Health. The study, which tested two doses of the drug in the male mice, found the higher dose to be toxic in the animals. Scientists emphasized that considerably more research is needed before the implications of metformin for healthy aging are known for humans. D., of the NIA’s Intramural Research Program, was published in the July 30, 2013 issue of Nature Communications. “It is exciting to discover that a drug already known to be safe and effective in humans might be further studied for a possible, alternate use for healthy aging.” Prescribed since the 1960s to treat type 2 diabetes, metformin is known to enhance insulin sensitivity, prompt sugar to be converted to energy, and prevent sugar build up in the liver. “There is increasing interest in exploring how drugs for one use might be repurposed for another,” notes Richard J. It also reduces risk of health issues associated with metabolic syndrome, a condition characterized by an increased chance for heart disease and stroke, as well as type 2 diabetes. “Aging is a driving force behind metabolic syndrome and diabetes. Given that metformin is clinically proven to alleviate symptoms of these conditions, and reduce risk of cancer, we thought perhaps it was a good candidate to study for its broader effects on health and lifespan,” said de Cabo. Specifically, de Cabo’s research focuses on testing compounds that might mimic benefits of calorie restriction, as shown in some animal models.
May be used in combination with a sulfonylurea, repaglinide, or thiazolidinedione antidiabetic agent for the management of type 2 diabetes mellitus in patients who do not achieve adequate glycemic control on monotherapy with metformin or any of these drugs. Commercially available in fixed combination with pioglitazone (as immediate- or extended-release tablets) for use as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who have inadequate glycemic control with pioglitazone or metformin monotherapy or in those who are already receiving pioglitazone and metformin concurrently as separate components. Commercially available in fixed combination with repaglinide for use as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who are already receiving repaglinide and metformin concurrently as separate components or in those who have inadequate glycemic control with repaglinide or metformin monotherapy. Potential advantages of metformin compared with sulfonylureas or insulin include minimal risk of hypoglycemia, more favorable effects on serum lipids, reduction of hyperinsulinemia, and weight loss or lack of weight gain. Scientific Advisory Panel of the Executive Committee, American Diabetes Association. Increase daily dosage in increments of one tablet (using the tablet strength at which therapy was initiated) at 2-week intervals until adequate glycemic control is achieved or maximum daily dosage of 2 g of metformin hydrochloride and 10 mg of glipizide is reached. Patients with inadequate glycemic control on either a sulfonylurea or metformin alone: Initially, 500 mg of metformin hydrochloride and 2.5 or 5 mg of glipizide twice daily with the morning and evening meals. Titrate daily dosage in increments not exceeding 500 mg of metformin hydrochloride and 5 mg of glipizide until adequate glycemic control achieved or maximum daily dosage of 2 g of metformin hydrochloride and 20 mg of glipizide is reached. Ovulation problems are one of those devastating problems that bother women. Being known as PCOS (Polycystic Ovary Syndrome), the condition affects the ability of a woman to get pregnant. Clomid, also known as Clomiphene, belongs to a group of the most appreciated fertility treatments on the contemporary market. Consulting a doctor, you will definitely get either Clomid or Metformin recommendation. The vast majority of women who address a doctor with ovulation problems get a prescription for Clomid. Commonly, the medication is recommended for 5-day use, particularly on the fifth-ninth days of the cycle. The results of numerous investigations show that over 80% of women taking Clomid start ovulating right after the treatment course, with about 40% getting pregnant within six following cycles. The beneficial point here is that Clomid can cause only a few minor side effects. Metformin (another name Glucophage) is another medication that is recommended for PCOS treatment.
Choosing among Metformin and Clomid as effective in PCOS, so one should pay a due attention to the combination of these two powerful drugs. Metformin Targets Multiple Pathways of Aging The ﬁgure depicts schematically the current consensus within the biology of aging community as to pathways that are important in order to target aging and indicates at which points metformin has been shown to have effects see text. Key take-away outside of the cell 1, top, metformin has been.